Mycophenolate Mofetil in Severe Atopic Dermatitis: A Review

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition causing significant morbidity and healthcare costs.
• While topical treatments and phototherapy are effective for many, a subset of patients requires systemic therapies.
• Refractory AD poses a treatment challenge, necessitating evaluation of alternative systemic options.

Purpose of the Study:

• To summarize existing evidence on the efficacy and safety of mycophenolate mofetil (MMF) for treating recalcitrant atopic dermatitis.
• To provide clinicians and patients with information to guide treatment decisions for severe AD cases.

Main Methods:

• Review of multiple studies investigating the use of mycophenolate mofetil (MMF) in patients with refractory atopic dermatitis.
• Analysis of data concerning both pediatric and adult populations with severe AD.

Main Results:

• Mycophenolate mofetil (MMF) has demonstrated promising results in managing severe and treatment-resistant atopic dermatitis.
• Evidence suggests MMF can be a viable systemic option for patients unresponsive to conventional therapies.

Conclusions:

• Mycophenolate mofetil (MMF) is a potential therapeutic option for recalcitrant atopic dermatitis in both children and adults.
• Understanding the benefits and risks of MMF is crucial for appropriate patient selection and treatment management.